Positive DehydraTECH GLP-1 animal studies cut GI adverse events by 31%100% Oral DehydraTECH-Rybelsus showed up to 100% GI AE reduction vs control DehydraTECH-tirzepatide oral formulations achieved 57% GI AE reductions in two studies DehydraTECH-semaglutide oral formulation reduced GI AEs by 43% vs Rybelsus DehydraTECH-liraglutide oral formulation cut GI AEs by 31% vs injectable Saxenda New 2026 animal studies initiated on retatrutide and amycretin with DehydraTECH Negative None
As research in this field continues to evolve, ongoing and future CVOTs will likely expand our knowledge of the cardiovascular benefits of GLP-1 receptor agonists, ultimately improving the care and outcomes of individuals with T2D and CVD
For climbers, I needed a sub clinical dose and I bet you might too
241 The oscillation of NAD + , in turn, coordinates the transcription and behavior through the circadian clock
Fernandez DM, Rahman AH, Fernandez NF, Chudnovskiy A, Amir ED, Amadori L, et al
Preconception diet, fertility, and later health in pregnancy